0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Coverage With Evidence Development What to Consider

Norman L. Foster, MD1; Karen Mottola, MA2; John M. Hoffman, MD3,4,5
[+] Author Affiliations
1Center for Alzheimer’s Care, Imaging, and Research, Department of Neurology, University of Utah, Salt Lake City
2Clinical Research Compliance and Education, University of Utah, Salt Lake City
3Department of Neurology, University of Utah, Salt Lake City
4Department of Radiology, University of Utah, Salt Lake City
5Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, Utah
JAMA Neurol. 2014;71(4):399-400. doi:10.1001/jamaneurol.2013.5812.
Text Size: A A A
Published online

Extract

Coverage with evidence development (CED) is a reimbursement mechanism the Centers for Medicare and Medicaid Services (CMS) is increasingly using for new technologies.1 The September 2013 CMS coverage decision for amyloid positron-emission tomography (PET) indicated that amyloid PET imaging under most circumstances will not be reimbursed. Reimbursement is possible only through CED in a CMS-approved study. Thus, many neurologists for the first time will face the decision of whether to participate in CED. We hope that sharing our experience with CED for use of 18fluorodeoxyglucose (FDG)-PET in the treatment of mild cognitive impairment through the Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) Study (eAppendix 1 in Supplement) will be instructive.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

438 Views
2 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();